{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T19:06:17Z","timestamp":1781118377776,"version":"3.54.1"},"reference-count":60,"publisher":"Informa UK Limited","issue":"10","license":[{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2023,7,3]]},"DOI":"10.1080\/14656566.2023.2215925","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T13:51:40Z","timestamp":1684849900000},"page":"1205-1214","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":7,"title":["Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy"],"prefix":"10.1080","volume":"24","author":[{"given":"Madeline","family":"Merkel","sequence":"first","affiliation":[{"name":"Alnylam Pharmaceuticals, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Danese","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongshu","family":"Chen","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie","family":"Wang","sequence":"additional","affiliation":[{"name":"Analysis Group, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aozhou","family":"Wu","sequence":"additional","affiliation":[{"name":"Analysis Group, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Yang","sequence":"additional","affiliation":[{"name":"Analysis Group, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hollis","family":"Lin","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,5,26]]},"reference":[{"issue":"7","key":"cit0001","first-page":"S107","volume":"23","author":"Gertz M.","year":"2017","journal-title":"Am J Manag Care"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-020-00273-y"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-8-31"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.3109\/07853890.2015.1068949"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26034"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2011-301299"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001870"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000289"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.038169"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.754348"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-018-0106-z"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26515"},{"key":"cit0013","unstructured":"Amyloidosis Research Consortium. The voice of the patient report: amyloidosis research consortium; 2016 [cited 2022 Jan 20]. Available from: https:\/\/arciorg.wpengine.com\/wp-content\/uploads\/2018\/05\/Voice-of-the-Patient.pdf"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8337-3"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716153"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716793"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2022.2091985"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182661eb1"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2022.2052838"},{"key":"cit0020","unstructured":"Jeffrey S FDA declines approval for tafamidis in TTR-FAP 2012 [cited 2021 Nov 14]. Available from: https:\/\/www.medscape.com\/viewarticle\/765981"},{"key":"cit0021","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1212\/WNL.96.15_supplement.1234","volume":"96","author":"Adams D","year":"2021","journal-title":"Neurology"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.326.7387.472"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1554648"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2020.1811850"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.04.002"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2014.01.004"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2017-0092"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.118.005095"},{"key":"cit0029","unstructured":"Wells G, Sultan S, Chen L, et al. Indirect evidence: indirect treatment comparisons in meta-analysis ottawa: Canadian Agency for Drugs and Technologies in Health; 2009 [cited 2022 Jan 22]. Available from: https:\/\/www.cadth.ca\/sites\/default\/files\/pdf\/H0462_itc_tr_e.pdf"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2017.1301419"},{"key":"cit0031","unstructured":"European Medicines Agency (EMA). Vyndaqel (tafamidis) 20 mg soft capsules: annex 1 Summary of product characteristics 2013 [cited 2021 Nov 1]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vyndaqel-epar-product-information_en.pdf"},{"key":"cit0032","unstructured":"European Medicines Agency (EMA). Public assessment report for Vyndaqel (tafamidis) 2011 [cited 2021 Nov 1]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/vyndaqel-epar-public-assessment-report_en.pdf"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-017-0948-5"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.116424"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.1.229"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2005.7.497"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1111\/jns5.12059"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25257"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2020.1730790"},{"key":"cit0040","first-page":"88","volume-title":"Amyloid and amyloidosis","author":"Coutinho P","year":"1980"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(12)60388-7"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-22886-6"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1994.tb01106.x"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.2217\/cer.13.89"},{"key":"cit0045","unstructured":"European Medicines Agency (EMA). Vyndaqel (tafamidis) EPAR Summary for the Public 2016 [cited 2021 Nov 1]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/vyndaqel-epar-summary-public_en.pdf"},{"key":"cit0046","unstructured":"Faria R, Walker S, Palmer S, et al. Tafamidis for transthyretin familial polyneuropathy (TTR-FAP) evidence review group assessment of manufacturer submission: cRD\/CHE Technology assessment group (centre for reviews and dissemination\/centre for health economics) University of York; 2012 [cited 2021 Dec 7]. Available from: https:\/\/www.york.ac.uk\/media\/crd\/Tafamidis%20ERG%20Report_CRDCHE%20September%204%202013.pdf"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1177\/1756285612470192"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(97)00049-8"},{"key":"cit0049","unstructured":"Phillippo D, Ades A, Dias S, et al. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE 2016 [cited 2021 Nov 6]. Available from: https:\/\/www.sheffield.ac.uk\/media\/34216\/download?attachment"},{"key":"cit0050","first-page":"803","volume":"112","author":"Kiefer C","year":"2015","journal-title":"Dtsch Arztebl Int"},{"key":"cit0051","unstructured":"International Conference on Harmonization (ICH). Choice of control group and related issues in clinical trials-E10 2000 [cited 2021 Nov 8]. Available from: https:\/\/database.ich.org\/sites\/default\/files\/E10_Guideline.pdf"},{"key":"cit0052","unstructured":"European Medicines Agency (EMA). Committee for medicinal products for human use: guideline on clinical trials in small populations 2006 [cited 2021 Nov 8]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-trials-small-populations_en.pdf"},{"key":"cit0053","unstructured":"United States Food and Drug Administration (FDA). Proposed FDA work plan for 21st century cures act innovation account activities 2016 [cited 2021 Nov 9]. Available from: https:\/\/www.fda.gov\/files\/Proposed-FDA-Work-Plan-for-21st-Century-Cures-Act-Innovation-Account-Activities-as-Submitted-to-Science-Board.pdf"},{"key":"cit0054","volume-title":"Prescribing information","author":"Amvuttra (Vutrisiran)","year":"2022"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1214\/20-AOAS1359"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2020-0236"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-138"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10635-1"},{"key":"cit0059","unstructured":"Adams D, Tournev I, Taylor M, et al. HELIOS-A: study of vutrisiran in patients with hATTR amyloidosis. 26\u00e8me \u00e9dition des Journ\u00e9es de la Soci\u00e9t\u00e9 Francophone du Nerf P\u00e9riph\u00e9rique (SFNP); 2022\/Jan\/21."},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2017.1357545"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2023.2215925","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T20:17:11Z","timestamp":1702498631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2023.2215925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,26]]},"references-count":60,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,7,3]]}},"alternative-id":["10.1080\/14656566.2023.2215925"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2023.2215925","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,26]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-01-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}